Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624879 · ClinicalTrials.gov registry record · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
A NA study of Grief, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 440
- Enrollment target
- 4
- Study locations
NCT05624879: Recruiting NA study of Grief, sponsored by Mayo Clinic.
NCT05624879 is a NA study of Grief that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 440 participants, below the 588-participant average among 12 other Grief trials with a reported enrollment target (25% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05624879, a NA study of Grief, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 440 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals following ART.
Primary Outcome
Measured by 14-item self-reported Prolonged Grief-12-Revised (PG-12-R) designed to measure the grief experience of current family caregivers of persons living with progressive disease. Total grief level scores greater than or equal to 30 indicate high levels of pre-loss grief.
Conditions Studied
Interventions
- BEHAVIORAL Accelerated Resolution Therapy
- OTHER Information and Support
Study Locations (4)
Florida
- Suncoast Hospice - Clearwater
- Mayo Clinic Florida - Jacksonville
Arizona
- Mayo Clinic Arizona - Phoenix
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2028-03-14 |
| Phase | NA |
What NCT05624879 shows while recruiting
NCT05624879 is an interventional study that assigns participants to a tested intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap, below the 588-participant average among 12 other Grief trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Grief appearing as the primary indexed condition, and to 2 interventions - of which Accelerated Resolution Therapy is the first listed.
NCT05624879 reports a single indexed study location in Florida, Arizona, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05624879 about?
NCT05624879 is a clinical study titled "Accelerated Resolution Therapy for Early Maladaptive Grief". The purpose study is to test the effects of accelerated resolution therapy (ART) on pre-loss grief and prolonged grief disorder among older adult family caregivers (FCGs). Additionally, to better understand predictors of response to ART, and cognitive processes that occur among grieving individuals ...
What is the current status of trial NCT05624879?
This trial is currently recruiting. It is a NA study. The enrollment target is 440 participants. The study started on 2023-11-17. Estimated completion is 2028-03-14.
What conditions does trial NCT05624879 study?
This clinical trial studies the following conditions: Grief.
What interventions are being tested in trial NCT05624879?
The interventions under investigation include: Accelerated Resolution Therapy (BEHAVIORAL), Information and Support (OTHER).
Who is sponsoring clinical trial NCT05624879?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624879 being conducted?
This trial has 4 study locations across Arizona, Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Grief
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05624879's enrollment target sits among peer trials
440 2nd of 12 the highest of 12 other Grief trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Grief trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Effects of Grieving
RECRUITING · NA
-
Improving Mental Health for Care Partners of Persons With AD/ADRD
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
-
Evaluation of Grief Therapy Approaches for Bereaved Parents
RECRUITING · NA
-
Support for Bereaved Cancer Caregivers
RECRUITING · NA
-
Telehealth to Reduce Mental Health in Family Caregivers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05783635 · 440 participants · NA
Alcohol Screening and Preoperative Intervention Research Study - 2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI